Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables (2020 - 2024)

Janux Therapeutics (JANX) has disclosed Receivables for 5 consecutive years, with $12.1 million as the latest value for Q2 2024.

  • On a quarterly basis, Receivables changed N/A to $12.1 million in Q2 2024 year-over-year; TTM through Jun 2024 was $12.1 million, a N/A change, with the full-year FY2023 number at $2.2 million, changed N/A from a year prior.
  • Receivables was $12.1 million for Q2 2024 at Janux Therapeutics, up from $4.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.1 million in Q2 2024 to a low of $400000.0 in Q2 2021.
  • A 5-year average of $4.0 million and a median of $2.2 million in 2023 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 450.62% in 2024; the steepest drop was 450.62% in 2024.
  • Janux Therapeutics' Receivables stood at $8.0 million in 2020, then tumbled by 95.0% to $400000.0 in 2021, then rose by 25.0% to $500000.0 in 2022, then skyrocketed by 332.2% to $2.2 million in 2023, then skyrocketed by 457.89% to $12.1 million in 2024.
  • Per Business Quant, the three most recent readings for JANX's Receivables are $12.1 million (Q2 2024), $4.4 million (Q1 2024), and $2.2 million (Q4 2023).